Urologic Consultants of Southeastern Pennsylvania
Welcome,         Profile    Billing    Logout  
 7 Trials 
15 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Belkoff, Laurence
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
NCT05799248: Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

Recruiting
3
113
US
rhPSMA-7.3 (18F), radiohybrid PSMA-targeted PET imaging agent, Radioligand for PET CT scanning
MidLantic Urology, Blue Earth Diagnostics
Prostate Cancer
05/24
05/24
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
DORA, NCT03574571 / 2018-002944-10: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Recruiting
3
700
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin
Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC
Urothelial Carcinoma
06/26
04/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT03914794: A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

Hourglass Jan 2021 - Dec 2021 : Updated data from trial for bladder cancer
Recruiting
2
43
US
Pemigatinib, INCB054828, FGFR inhibitor INCB054828
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
05/25
05/26
NCT06567743: Brief Title: Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Recruiting
2
50
US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
High-Risk Non-Muscle-Invasive Bladder Cancer
03/27
12/27
NCT03945162: Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Recruiting
2
125
Canada, US
Ruvidar® (TLD-1433) Bladder infusion and PDT
Theralase® Technologies Inc., University Health Network, Toronto, Pharma eMarket
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
06/25
12/25
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
NCT05250908: INTIBIA Pivotal Study

Active, not recruiting
N/A
208
Europe, US
INTIBIA Therapeutic, INTIBIA Non-Therapeutic
Coloplast A/S
Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
06/25
06/26
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Active, not recruiting
N/A
400
US
Vanquish System
Francis Medical Inc.
Prostate Cancer
04/27
04/29

Download Options